Following promising trial results, retatrutide, a novel peptide therapy for managing non-insulin dependent metabolic disorder, has secured regulatory approval from UK’s Drug and Healthcare Agency (MHRA https://harleylcld508808.ltfblog.com/39450163/retatrutide-medication-peptide-uk-authorization-and-launch